In collaboration with Mundipharma, the MM working group of the BHS created a medical need program for Levact (bendamustine). This program has been set up for patients that relapsed after Velcade and Revlimid treatment. In total 20 patients can be treated in 2012, therefore each centre can maximally enrol 2 patients. The procedure is explained in the introductory letter.
- Introductory letter
- Protocol and contract
- Patient consent form FR
- Patient consent form NL
- BHS request form
- Mundipharma initial request form
- Munidpharma FU cycle request form